This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Driscoll, D. F. Search for Related Content PubMed PubMed Citation Articles by Driscoll, D. F. Social Bookmarking                         What's this?

Lipid Injectable Emulsions: 2006

Department of Medicine, Division of Clinical Nutrition, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts

Correspondence: Correspondence: David F. Driscoll, PhD, Department of Medicine, Division of Clinical Nutrition, Beth Israel Deaconess Medical Center, Baker Building, Suite 605, One Deaconess Road, Boston, MA 02215. Electronic mail may be sent to ddriscol{at}caregroup.harvard.edu.

Lipid injectable emulsions are an essential source of fatty acids, as well as a daily source of calories. They have been used in the clinical setting for almost 40 years, but despite this, there are no established official standards governing pharmaceutical quality. After 15 years of development, the United States Pharmacopeia (USP), which writes such standards for all FDA-approved pharmaceuticals, is poised to adopt an official monograph for lipid injectable emulsions that sets pharmaceutical requirements on all manufacturers placing limits on pH, free fatty acid concentrations and globule size (both mean droplet size and the population of large fat globules larger than 5 micrometers). Recent animal data has shown pathophysiologic changes in vital organs for lipids that fall outside the USP-proposed globule size limits. From a clinical perspective, newer lipid injectable emulsions show great promise in certian patient settings, most notably in the intensive care unit in both adults and infants. The clinical use of alternative oils, such as medium-chain triglycerides, fish oil and olive oil show benefits over conventional soybean oil formulations. In adults, for example, the administration of -fatty acids via soybean oil-based lipids produces a heightened inflammatory response via production of 2-series prostaglandins, whereas substitution of a portion of the lipid with -3 fatty acids via fish oil can favorably dampen the inflammatory response. In infants, for example, substitution of soybean oil with fish oil has recently been shown to reverse parenteral nutrition-associated liver disease. These advances should lead to safer infusion therapy in patients receiving lipid injectable emulsions.

Nutrition in Clinical Practice, Vol. 21, No. 4, 381-386 (2006)
DOI: 10.1177/0115426506021004381


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Gallegos, P. Partal, and J. M. Franco Droplet-size distribution and stability of lipid injectable emulsions Am. J. Health Syst. Pharm., January 15, 2009; 66(2): 162 - 166. [Abstract] [Full Text] [PDF]

				S. D. Chaieb, J.-C. Chaumeil, S. Jebnoun, N. Khrouf, A. Hedhili, and S. Sfar Effect of High Calcium and Phosphate Concentrations on the Physicochemical Properties of Two Lipid Emulsions Used as Total Parenteral Nutrition for Neonates PDA J. Pharm. Sci. Technol., January 1, 2009; 63(1): 27 - 41. [Abstract] [Full Text] [PDF]

				S. J. Brull Lipid Emulsion for the Treatment of Local Anesthetic Toxicity: Patient Safety Implications Anesth. Analg., May 1, 2008; 106(5): 1337 - 1339. [Full Text] [PDF]

				G. P. Zaloga, A. J. Dunham, T. M. Gonyon, L. M. Best, and M. Groves Safety and Stability of Lipid Emulsions Nutr Clin Pract, June 1, 2007; 22(3): 367 - 369. [Full Text] [PDF]

				D. F. Driscoll Safety and Stability of Lipid Emulsions--Response Nutr Clin Pract, June 1, 2007; 22(3): 370 - 372. [Full Text]